New triple-drug attack aims to revive immune response in hard-to-treat melanoma
NCT ID NCT04562129
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether combining high-dose interleukin-2 with low-dose ipilimumab, followed by nivolumab, can shrink tumors in people with advanced melanoma that has stopped responding to prior immunotherapy. About 29 participants with inoperable stage III or IV melanoma will receive the drug combination over 12-week courses. The main goal is to see how many patients experience tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Interleukin-2 (aldesleukin), ipilimumab, and nivolumab
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced melanoma that no longer responds to standard immunotherapy.
- What could go wrong
- This is a small, early-phase trial with only 29 participants, so results may not apply widely. The combination of drugs can cause severe side effects, including immune system overactivation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INOPERABLE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
- Can interferon keep melanoma from coming back after surgery?
- Pee power: urine bacteria may predict melanoma treatment success
- New Pill-and-Immunotherapy combo aims to shrink melanoma before surgery
- New rectal cancer device tested in elderly patients
- Experimental virus therapy takes on advanced cancers in first human trial